Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect

Autor: de la Morena‐Barrio, M.E., Martínez‐Martínez, I., de Cos, C., Wypasek, E., Roldán, V., Undas, A., van Scherpenzeel, M., Lefeber, D.J., Toderici, M., Sevivas, T., España, F., Jaeken, J., Corral, J. ^*, Vicente, V.

Publikováno v: In Journal of Thrombosis and Haemostasis August 2016 14(8):1549-1560

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

Autor: Gerotziafas G. T., Catalano M., Colgan M. -P., Pecsvarady Z., Wautrecht J. C., Fazeli B., Olinic D. -M., Farkas K., Elalamy I., Falanga A., Fareed J., Papageorgiou C., Arellano R. S., Agathagelou P., Antic D., Auad L., Banfic L., Bartolomew J. R., Benczur B., Bernardo M. B., Boccardo F., Cifkova R., Cosmi B., De Marchi S., Dimakakos E., Dimopoulos M. A., Dimitrov G., Durand-Zaleski I., Edmonds M., El Nazar E. A., Erer D., Esponda O. L., Gresele P., Gschwandtner M., Gu Y., Heinzmann M., Hamburg N. M., Hamade A., Jatoi N. -A., Karahan O., Karetova D., Karplus T., Klein-Weigel P., Kolossvary E., Kozak M., Lefkou E., Lessiani G., Liew A., Marcoccia A., Marshang P., Marakomichelakis G., Matuska J., Moraglia L., Pillon S., Poredos P., Prior M., Salvador D. R. K., Schlager O., Schernthaner G., Sieron A., Spaak J., Spyropoulos A., Sprynger M., Suput D., Stanek A., Stvrtinova V., Szuba A., Tafur A., Vandreden P., Vardas P. E., Vasic D., Vikkula M., Wennberg P., Zhai Z., Bikdeli B., Guo Y., Harenberg J., Hu Y., Lip G. Y. H., Roldan V.

Publikováno v: Thrombosis and Haemostasis
Thrombosis and Haemostasis, Schattauer, 2020, 120 (12), pp.1597-1628. ⟨10.1055/s-0040-1715798⟩
Thrombosis and haemostasis, Vol. 120, no. 12, p. 1597-1628 (2020)

COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55f4f5a102cb0bb063d3bcdc3fb1d247
https://pubmed.ncbi.nlm.nih.gov/32920811

Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper

Autor: Gorog, DA, Gue, YX, Chao, TF, Fauchier, L, Ferreiro, JL, Huber, K, Konstantinidis, SV, Lane, DA, Marin, F, Oldgren, J, Potpara, T, Roldan, V, Rubboli, A, Sibbing, D, Tse, HF, Vilahur, G, Lip, GYH

Publikováno v: THROMBOSIS AND HAEMOSTASIS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

While there is a clear clinical benefit of oral anticoagulation in patients with atrial fibrillation (AF) and venous thromboembolism (VTE) in reducing the risks of thromboembolism, major bleeding events (especially intracranial bleeds) may still occu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::d1dd3a2e3f5c71c847cb71a4fd2f375f
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11961